Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Feb 2025 Status changed from recruiting to completed.
10 Sep 2024 According to QurAlis Corporation media release, the company anticipates reporting topline data from the Phase 1 MAD clinical trial of QRL-101 in the first half of 2025
10 Sep 2024 According to QurAlis Corporation media release, The dose range of QRL-101 for this MAD study was determined by results from QurAlis Phase 1 single-ascending dose (SAD) clinical trial (QRL-101-01; NCT05667779).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com